Vanderbilt Ingram Cancer Center Archives
Aug. 15, 2019—A study led by Anna Vilgelm, MD, PhD, and Ann Richmond, PhD, has identified a possible second-line treatment for melanoma patients.
Aug. 7, 2019—Younger patients say colorectal cancer is a disease that doesn’t follow age guidelines, so pay attention to early symptoms.
Aug. 1, 2019—The Vietnamese Ministry of Health has awarded two Vanderbilt epidemiologists the Memorabilia Medal “For the People’s Health” in appreciation for their contributions in helping the nation establish a population-based research program for cancer, diabetes and other non-communicable diseases.
Aug. 1, 2019—Michael Savona, MD, has received a competitive grant to develop therapies for patients with myelodysplastic syndromes.
Jul. 22, 2019—Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.
Jul. 8, 2019—A clinical study of a drug that may block cancer metastasis is currently enrolling patients at the Vanderbilt-Ingram Cancer Center.
Jun. 13, 2019—More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.
Jun. 13, 2019—Cathy Eng, MD, a national and international leader in gastrointestinal medical oncology, is joining Vanderbilt-Ingram Cancer Center (VICC).
Jun. 13, 2019—The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment. VUMC's Madan Jagasia, MBBS, MS, MMHC, was a lead investigator of the REACH1 trial that was the basis for the FDA approval.
Jun. 6, 2019—Nine years after being diagnosed with metastatic lung cancer, Roszell Mack Jr., 87, still goes into the office every day thanks to a durable response to the immunotherapy pembrolizumab.